Trends in compulsory licensing of pharmaceuticals because the doha declaration: a database analysis

by Posted on
Trends in compulsory licensing of pharmaceuticals because the doha declaration: a database analysis World Trade
  1. 1.

    World Trade Organization (2001 November 20) Declaration around the Journeys agreement and public health. Available: http://www.wto.org/british/thewto_e/minist_e/min01_e/mindecl_journeys_e.htm. Utilized 3 September 2011.

  2. 2.

    World Trade Organization (2003 September 1) Implementation of paragraph 6 from the Doha Declaration around the Journeys Agreement and public health. Available: http://www.wto.org/british/tratop_e/journeys_e/implem_para6_e.htm. Utilized 3 September 2011.

  3. 3.

    Banta D (2001) Public health triumphs at WTO Conference. JAMA 286: 2655–2656.

    • View Article

    • Google Scholar

  4. 4.

    Kanth R (2003 September 2) WTO drug deal to spark competition. Business Occasions Singapore.

  5. 5.

    Attaran A (2004) How can patents and economic policies affect use of essential medicines in developing countries? Health Aff 23: 155–166.

    • View Article

    • Google Scholar

  6. 6.

    World Trade Organization (2011) Ip: protection and enforcement. Available: http://www.wto.org/british/thewto_e/whatis_e/tif_e/agrm7_e.htm. Utilized 3 September 2011.

  7. 7.

    Correa C (2003) Handling the provision of understanding: the style of ip laws and regulations. In: Kaul I, Conceicao P, Le Goulven K, Mendoza RU, editors. Supplying global public goods: managing globalization. Oxford: Oxford College Press. pp. 410–430.

  8. 8.

    World Health Organization (2008 Feb) Briefing note: use of medicines—country encounters in making use of Journeys safeguards. Available: http://www.searo.who.int/LinkFiles/IPT_Briefing_note_4_country_encounters.pdf. Utilized 3 September 2011.

  9. 9.

    World Trade Organization (2006 September) Journeys and pharmaceutical patents: obligations and exceptions. Available: http://www.wto.org/british/tratop_e/journeys_e/factsheet_pharm02_e.htm#art31. Utilized 3 September 2011.

  10. 10.

    World Trade Organization (2006 September 21) Pharmaceutical patents and also the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/pharma_ato186_e.htm. Utilized 3 September 2011.

  11. 11.

    World Trade Organization (2011) Faq’s about Journeys. Available: http://www.wto.org/british/tratop_e/journeys_e/tripfq_e.htm#Transition. Utilized 3 September 2011.

  12. 12.

    World Trade Organization (2011) Developing countries’ transition periods. Available: http://www.wto.org/british/tratop_e/journeys_e/factsheet_pharm04_e.htm. Utilized 3 September 2011.

  13. 13.

    Murthy D (2002) The way forward for compulsory licensing: deciphering the Doha Declaration around the Journeys Agreement and public health. Am Univ Int Law Rev 17: 1299–1346.

    • View Article

    • Google Scholar

  14. 14.

    Harmon A, Pear R (2001 October 19) Canada overrides patent for Cipro to deal with anthrax. New You are able to Occasions. Available: http://www.nytimes.com/2001/10/19/business/19CANA.html. Utilized 3 April 2011.

  15. 15.

    Curti AM (2001) The WTO dispute settlement understanding: an unlikely weapon in fighting against AIDS. Am J Law Mediterranean 27: 469–485.

    • View Article

    • Google Scholar

  16. 16.

    Correa C (2002 June) Implications from the Doha Declaration around the Journeys Agreement and Public Health. Health financial aspects and medicines series, no. 012. Geneva: World Health Organization. Available: http://apps.who.int/medicinedocs/en/d/Js2301e/. Utilized 3 September 2011.

  17. 17.

    World Trade Organization (2001 November 9–13) Press pack—4th Ministerial Conference Doha. Available: http://www.wto.org/british/thewto_e/minist_e/min01_e/brief_e/doha_presspack_e.pdf. Utilized 3 September 2011.

  18. 18.

    World Trade Organization (2005 December 8) Amendment from the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/wtl641_e.htm. Utilized 3 September 2011.

  19. 19.

    World Trade Organization (2009 December 18) Amendment from the Journeys Agreement—second extension from the period for that acceptance of people from the protocol amending the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/wt-l-785_e.pdf. Utilized 3 September 2011.

  20. 20.

    World Trade Organization (2011) Journeys and public health news archive. Available: http://www.wto.org/british/news_e/archive_e/journeys_health_arc_e.htm. Utilized 3 September 2011.

  21. 21.

    Reich MR2000 March17The global drug gap. Science 287: 1979–1981. Available: http://134.174.190.199/faculty/michael-reich/files/global_drug_gap.pdf. Utilized 3 September 2011.

    • View Article

    • Google Scholar

  22. 22.

    Cohen JC, Gyansa-Lutterodt M, Torpey K, Esmail LC, Kurokawa G (2005 December 9) Journeys, the Doha Declaration and growing use of medicines: policy choices for Ghana. Global Health 1: 17. Available: http://www.biomedcentral.com/content/pdf/1744-8603-1-17.pdf. Utilized 3 September 2011.

    • View Article

    • Google Scholar

  23. 23.

    Cruz RD, Correa C, Oh C (2009) Trade, Journeys, and pharmaceuticals. Lancet 373: 684–691.

    • View Article

    • Google Scholar

  24. 24.

    World Health Organization (2011) WHO model lists of essential medicines. Available: http://www.who.int/medicines/publications/essentialmedicines/en/. Utilized 4 December 2011.

  25. 25.

    Oliveira MA, Bermudez JAZ, Chaves GC, Velásquez G (2004) Has got the implementation from the Journeys agreement in South America and also the Caribbean created ip legislation that favours public health? Bull World Health Organ 82: 815–821.

    • View Article

    • Google Scholar

  26. 26.

    Chaves GC, Oliveira MA (2007) An offer for calculating the quality of public health-sensitivity of patent legislation poor the WTO Journeys Agreement. Bull World Health Organ 85: 49–56.

    • View Article

    • Google Scholar

  27. 27.

    Van Gelder A, Stevens P (2010 November) The compulsory license red sardines. London: Worldwide Policy Network. Available: http://www.minimalgovernment.internet/media/compulsory-201011.pdf. Utilized 11 June 2011.

  28. 28.

    Consumer Project on Technology (2010) Healthcare and ip: compulsory licensing. Available: http://www.cptech.org/ip/health/cl/. Utilized 3 April 2011.

  29. 29.

    Bucknell D (2007 October 22) The worldwide IP scorecard for pharma and biotech compulsory licenses. Mondaq Business Briefing. Available: http://www.mondaq.com/australia/article.asp?articleid=53442. Utilized 3 April 2011.

  30. 30.

    Beall R (2010) Trends in worldwide compulsory licensing for pharmaceuticals because the institution from the Trade Related Facets of Ip Legal rights (Journeys) Agreement [Master’s thesis]. Denver: Josef Korbel School of Worldwide Studies, Global Health Matters, College of Denver.

  31. 31.

    LexisNexis (2011) About us. Available: http://www.lexisnexis.com/about-us/. Utilized 3 September 2011.

  32. 32.

    World Trade Organization (2010) Journeys and public health ‘paragraph 6’ system: notifications by importing WTO people. Available: http://www.wto.org/british/tratop_e/journeys_e/public_health_notif_import_e.htm. Utilized 3 September 2011.

  33. 33.

    Hestermeyer HP (2007 December) Canadian-made drugs for Rwanda: the very first use of the WTO waiver on patents and medicines. Am Soc Int Law Insights 10: Available: http://www.asil.org/insights/2007/12/insights071210.html. Utilized 3 September 2011.

    • View Article

    • Google Scholar

  34. 34.

    Sekalala SR (2010 Feb) Under developed use of essential medicines and also the WTO General Council Decision 2003. King’s Law J 21: 172–192.

    • View Article

      Trends in compulsory licensing of pharmaceuticals because the doha declaration: a database analysis World Trade
      1. 1.

        World Trade Organization (2001 November 20) Declaration around the Journeys agreement and public health. Available: http://www.wto.org/british/thewto_e/minist_e/min01_e/mindecl_journeys_e.htm. Utilized 3 September 2011.

      2. 2.

        World Trade Organization (2003 September 1) Implementation of paragraph 6 from the Doha Declaration around the Journeys Agreement and public health. Available: http://www.wto.org/british/tratop_e/journeys_e/implem_para6_e.htm. Utilized 3 September 2011.

      3. 3.

        Banta D (2001) Public health triumphs at WTO Conference. JAMA 286: 2655–2656.

        • View Article

        • Google Scholar

      4. 4.

        Kanth R (2003 September 2) WTO drug deal to spark competition. Business Occasions Singapore.

      5. 5.

        Attaran A (2004) How can patents and economic policies affect use of essential medicines in developing countries? Health Aff 23: 155–166.

        • View Article

        • Google Scholar

      6. 6.

        World Trade Organization (2011) Ip: protection and enforcement. Available: http://www.wto.org/british/thewto_e/whatis_e/tif_e/agrm7_e.htm. Utilized 3 September 2011.

      7. 7.

        Correa C (2003) Handling the provision of understanding: the style of ip laws and regulations. In: Kaul I, Conceicao P, Le Goulven K, Mendoza RU, editors. Supplying global public goods: managing globalization. Oxford: Oxford College Press. pp. 410–430.

      8. 8.

        World Health Organization (2008 Feb) Briefing note: use of medicines—country encounters in making use of Journeys safeguards. Available: http://www.searo.who.int/LinkFiles/IPT_Briefing_note_4_country_encounters.pdf. Utilized 3 September 2011.

      9. 9.

        World Trade Organization (2006 September) Journeys and pharmaceutical patents: obligations and exceptions. Available: http://www.wto.org/british/tratop_e/journeys_e/factsheet_pharm02_e.htm#art31. Utilized 3 September 2011.

      10. 10.

        World Trade Organization (2006 September 21) Pharmaceutical patents and also the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/pharma_ato186_e.htm. Utilized 3 September 2011.

      11. 11.

        World Trade Organization (2011) Faq’s about Journeys. Available: http://www.wto.org/british/tratop_e/journeys_e/tripfq_e.htm#Transition. Utilized 3 September 2011.

      12. 12.

        World Trade Organization (2011) Developing countries’ transition periods. Available: http://www.wto.org/british/tratop_e/journeys_e/factsheet_pharm04_e.htm. Utilized 3 September 2011.

      13. 13.

        Murthy D (2002) The way forward for compulsory licensing: deciphering the Doha Declaration around the Journeys Agreement and public health. Am Univ Int Law Rev 17: 1299–1346.

        • View Article

        • Google Scholar

      14. 14.

        Harmon A, Pear R (2001 October 19) Canada overrides patent for Cipro to deal with anthrax. New You are able to Occasions. Available: http://www.nytimes.com/2001/10/19/business/19CANA.html. Utilized 3 April 2011.

      15. 15.

        Curti AM (2001) The WTO dispute settlement understanding: an unlikely weapon in fighting against AIDS. Am J Law Mediterranean 27: 469–485.

        • View Article

        • Google Scholar

      16. 16.

        Correa C (2002 June) Implications from the Doha Declaration around the Journeys Agreement and Public Health. Health financial aspects and medicines series, no. 012. Geneva: World Health Organization. Available: http://apps.who.int/medicinedocs/en/d/Js2301e/. Utilized 3 September 2011.

      17. 17.

        World Trade Organization (2001 November 9–13) Press pack—4th Ministerial Conference Doha. Available: http://www.wto.org/british/thewto_e/minist_e/min01_e/brief_e/doha_presspack_e.pdf. Utilized 3 September 2011.

      18. 18.

        World Trade Organization (2005 December 8) Amendment from the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/wtl641_e.htm. Utilized 3 September 2011.

      19. 19.

        World Trade Organization (2009 December 18) Amendment from the Journeys Agreement—second extension from the period for that acceptance of people from the protocol amending the Journeys Agreement. Available: http://www.wto.org/british/tratop_e/journeys_e/wt-l-785_e.pdf. Utilized 3 September 2011.

      20. 20.

        World Trade Organization (2011) Journeys and public health news archive. Available: http://www.wto.org/british/news_e/archive_e/journeys_health_arc_e.htm. Utilized 3 September 2011.

      21. 21.

        Reich MR2000 March17The global drug gap. Science 287: 1979–1981. Available: http://134.174.190.199/faculty/michael-reich/files/global_drug_gap.pdf. Utilized 3 September 2011.

        • View Article

        • Google Scholar

      22. 22.

        Cohen JC, Gyansa-Lutterodt M, Torpey K, Esmail LC, Kurokawa G (2005 December 9) Journeys, the Doha Declaration and growing use of medicines: policy choices for Ghana. Global Health 1: 17. Available: http://www.biomedcentral.com/content/pdf/1744-8603-1-17.pdf. Utilized 3 September 2011.

        • View Article

        • Google Scholar

      23. 23.

        Cruz RD, Correa C, Oh C (2009) Trade, Journeys, and pharmaceuticals. Lancet 373: 684–691.

        • View Article

        • Google Scholar

      24. 24.

        World Health Organization (2011) WHO model lists of essential medicines. Available: http://www.who.int/medicines/publications/essentialmedicines/en/. Utilized 4 December 2011.

      25. 25.

        Oliveira MA, Bermudez JAZ, Chaves GC, Velásquez G (2004) Has got the implementation from the Journeys agreement in South America and also the Caribbean created ip legislation that favours public health? Bull World Health Organ 82: 815–821.

        • View Article

        • Google Scholar

      26. 26.

        Chaves GC, Oliveira MA (2007) An offer for calculating the quality of public health-sensitivity of patent legislation poor the WTO Journeys Agreement. Bull World Health Organ 85: 49–56.

        • View Article

        • Google Scholar

      27. 27.

        Van Gelder A, Stevens P (2010 November) The compulsory license red sardines. London: Worldwide Policy Network. Available: http://www.minimalgovernment.internet/media/compulsory-201011.pdf. Utilized 11 June 2011.

      28. 28.

        Consumer Project on Technology (2010) Healthcare and ip: compulsory licensing. Available: http://www.cptech.org/ip/health/cl/. Utilized 3 April 2011.

      29. 29.

        Bucknell D (2007 October 22) The worldwide IP scorecard for pharma and biotech compulsory licenses. Mondaq Business Briefing. Available: http://www.mondaq.com/australia/article.asp?articleid=53442. Utilized 3 April 2011.

      30. 30.

        Beall R (2010) Trends in worldwide compulsory licensing for pharmaceuticals because the institution from the Trade Related Facets of Ip Legal rights (Journeys) Agreement [Master’s thesis]. Denver: Josef Korbel School of Worldwide Studies, Global Health Matters, College of Denver.

      31. 31.

        LexisNexis (2011) About us. Available: http://www.lexisnexis.com/about-us/. Utilized 3 September 2011.

      32. 32.

        World Trade Organization (2010) Journeys and public health ‘paragraph 6’ system: notifications by importing WTO people. Available: http://www.wto.org/british/tratop_e/journeys_e/public_health_notif_import_e.htm. Utilized 3 September 2011.

      33. 33.

        Hestermeyer HP (2007 December) Canadian-made drugs for Rwanda: the very first use of the WTO waiver on patents and medicines. Am Soc Int Law Insights 10: Available: http://www.asil.org/insights/2007/12/insights071210.html. Utilized 3 September 2011.

        • View Article

        • Google Scholar

      34. 34.

        Sekalala SR (2010 Feb) Under developed use of essential medicines and also the WTO General Council Decision 2003. King’s Law J 21: 172–192.

        • View Article

        • Google Scholar

      35. 35.

        Ayodele T (2008 April 28) Africa’s failing infrastructure renders compulsory licensing pointless. The Brand New Occasions (Kigali, Rwanda). Available: http://www.newtimes.co.rw/index.php?issue=13515&article=5935. Utilized 29 November 2011.

      36. 36.

        Dugger CW (2007 May 9) Clinton Foundation announces a good deal on generic AIDS drugs. New You are able to Occasions. Available: http://www.nytimes.com/2007/05/09/world/09aidsdrugs.html. Utilized 3 September 2011.

      37. 37.

        Waning B, Diedrichsen E, Moon S (2010 September 14) A lifeline to treatment: the function of Indian generic manufacturers in offering antiretroviral medicines to developing countries. J Int AIDS Soc 13: 35. Available: http://www.jiasociety.org/content/13/1/35. Utilized 3 September 2011.

        • View Article

        • Google Scholar

      38. 38.

        Savoie B (2007) Thailand’s test: compulsory licensing within an era from the epidemiological transition. Veterans administration J Int Law 48: 211–248.

        • View Article

        • Google Scholar

      39. 39.

        Commission on Ip Legal rights, Innovation and Public Health (2006 April) Public health: innovation and ip legal rights. Geneva: World Health Organization. Available: http://www.who.int/intellectualproperty/documents/thereport/CIPIH23032006.pdf. Utilized 3 April 2011.

      Resourse: https://journals.plos.org/plosmedicine/article?id=10.1371/

      Trends in compulsory licensing of pharmaceuticals because the doha declaration: a database analysis Worldwide Policy Network

      Understanding Compulsory Licensing

      Related Posts:

      • resolution-to-combat-counterfeit-pharmaceuticals_2.jpg
      • world-ip-day-is-april-26_1.jpg
      • world-mental-health-day-initiatives-and-updates_1.jpg
      • the-twin-results-of-ip-rules-within-and-between_2.jpg
      • safeguard-the-drug-giants-patents-and-harm-the_1.jpg
      • why-chinas-new-legal-framework-is-a-magnet-for_1.jpg
      • how-do-you-make-use-of-the-reliable-ip-systems_1.jpg
      • what-s-blockchain-s-role-later-on-of-ip_1.jpg

Published by alex